Abstract Library

#4475 Retreatment with [177Lu]Lu-DOTATATE in neuroendocrine tumours: Outcomes in progression-free survival and toxicity – Our experience

Introduction: Multiple systemic treatments exist for advanced or metastatic NETs, including somatostatin analogues, targeted agents, chemotherapy, and peptide receptor radionuclide therapy (PRRT). PRRT has shown maximum benefit for response rate, progression-free survival (PFS), and overall survival (OS) with favourable toxicity.

Conference:

Presenting Author: Salcedo Cortes S

Authors: Salcedo Cortes S, Mari Hualde A, Ardila Manjarés E, Guzman Cruz A, Orcajo Rincón J,

Keywords: Neuroendocrine tumour (NET), Peptide receptor radionuclide therapy (PRRT), [177Lu]Lu-DOTATATE, Retreatment (R-PRRT), Toxicity, Progression-free survival (PFS), Overall survival (OS),

#4370 Role of 68GA-DOTATOC pet/ct in therapeutic decision-making for well-differentiated neuroendocrine tumours

Introduction: 68Ga-DOTATOC PET/CT is a highly sensitive and specific test for assessing gastroenteropancreatic and pulmonary neuroendocrine tumours (NET) expressing somatostatin receptors.

Conference:

Presenting Author: Cruz-Diaz W

Authors: Cruz Diaz W, Landaeta Kancev L, Martinez-Amores Martínez B, Bastidas Tamayo J, Estrella Santos A,

Keywords: 68Ga-DOTATOC PET/CT, well-differentiated, gastroenteropancreatic, pulmonary, neuroendocrine tumour, Lu-177-DOTATATE,

#4356 Assessment of medium- and long-term side effects of Lu-177 treatment in patients with neuroendocrine tumours

Introduction: PRRT with Lu-177 has advanced the treatment of neuroendocrine tumours (NETs), adding a valuable tool against them. This study aims to assess its long-term impact, especially on the most radio-exposed organs—kidneys and bone marrow—and the reproducibility of in vivo clinical trial results (PFS).

Conference:

Presenting Author: Salcedo Cortes S

Authors: Salcedo Cortes S, Ardila Manjarés E, Mari Hualde A, Guzman Cruz A, Casallas Cepeda M,

Keywords: Neuroendocrine tumour (NET), [177Lu]Lu-DOTATATE, Long-term side effects, Radiosensitive organs, PFS,

#4286 Clinicopathologic characteristics and survival outcomes in patients with gastroenteropancreatic neuroendocrine neoplasms at a Latin American reference centre

Introduction: Neuroendocrine neoplasms (NEN) have markedly increased over the past two decades. However, published data from Latin American countries remain scarce.

Conference:

Presenting Author: Cruz Diaz W

Authors: Cruz Diaz W, Paitan Amaro V, Haro Varas J, Macetas Núñez J, Leonardo Carbajal A,

Keywords: Well-differentiated, Gastroenteropancreatic neuroendocrine tumour, Retrospective study, overall survival,

#3677 Myelophthisis as an end-stage outcome of rare metastases in neuroendocrine tumors – A dual case report

Introduction: Intra-abdominal Neuroendocrine Tumors (NETs) usually metastasize to regional lymph nodes, liver, and bone. Myelophthisis (MPT) is the destruction of the medullary microenvironment due to the tumoral invasion of the trabecular space, altering normal hematopoiesis; it’s frequently caused by metastasis of breast, prostate, and lung adenocarcinomas, and neuroblastoma. MPT due to NET is an unrecognized phenomenon with few cases reported, almost exclusively in poorly differentiated NETs.

Conference:

Presenting Author:

Authors: González Devia D, Aldana-Gómez L, Segovia Gómez J, Ortiz-Santacruz C, Mejía-Arango M,

Keywords: Neuroendocrine Tumor, Myelophthisis, Colon tumor, Prostate tumor, End-stage,